Audrey Andrews
Authored Items
Based on research presented at the 2018 National Comprehensive Cancer Network Annual Conference, patients weighing 60 kg to 85 kg who often receive lower-than-recommended doses of filgrastim, without evidence of its noninferiority to recommended doses, is found to be not only acceptable, but also cost-saving.
Read Bio ›Hollywood, FL—Results from a survey of oncology pharmacists from across the country indicate that the verification process for chemotherapy orders is not uniformly electronic. In fact, >25% of responders are still using paper orders, said Carly Duncan, PharmD candidate, of the Cleveland Clinic Florida, Weston. She presented findings from her and her colleagues’ survey at the 2016 annual conference of the National Comprehensive Cancer Network.
Read Bio ›Hollywood, FL—In a study presented at the 2016 annual conference of the National Comprehensive Cancer Network, a real-world assessment of lenalidomide use in the treatment of patients with myelodysplastic syndrome (MDS) showed that dose modifications had a strong positive effect on outcomes.
Read Bio ›CHICAGO—Women considered at risk for breast cancer developed fewer breast cancers and fewer precursor lesions by taking the aromatase inhibitor (AI) exemestane for 5 years, versus placebo, in a large Canadian study presented at the 2011 annual meeting of the American Society of Clinical Oncology.
Read Bio ›
CHICAGO—More support for bevacizumab in the treatment of ovarian cancer emerged at the 2011 annual meeting of the American Society of Clinical Oncology, with studies showing the drug prolongs the time to disease progression, both in the metastatic and primary disease settings.
OCEANS
Read Bio ›CHICAGO—For the first time in decades, the treatment of advanced melanoma has taken a positive turn, according to studies presented at the 2011 annual meeting of the American Society of Clinical Oncology that showed a survival benefit with 2 experimental agents.
Read Bio ›
CHICAGO—The oral poly (ADP-ribose) polymerase (PARP) inhibitor olaparib delayed ovarian cancer recurrence by 4 months when given as maintenance therapy to patients with platinum-sensitive relapsed ovarian cancer, in an international study reported at the 2011 annual meeting of the American Society of Clinical Oncology by Jonathan Ledermann, MD, professor of medical oncology, University College London, United Kingdom.
Read Bio ›
The evidence backing the use of myeloid growth factors in patients at high risk for febrile neutropenia is solid, according to Jeffrey Crawford, MD, of Duke Cancer Institute, Durham, North Carolina.
Read Bio ›